Deutsche Märkte geschlossen

Sanofi (SAN.PA)

Paris - Paris Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
95,48-1,37 (-1,41%)
Börsenschluss: 05:35PM CEST

Sanofi

54, Rue La BoEtie
Paris 75008
France
33 1 53 77 40 00
https://www.sanofi.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—General
Vollzeitmitarbeiter95.442

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Paul HudsonCEO & Director5,64MN/A1967
Mr. Jean-Baptiste Chasseloup de ChatillonExec. VP & CFON/AN/A1965
Mr. Laurent GilhodesPrincipal Accounting Officer and VP of Corp. AccountingN/AN/AN/A
Mr. Bruno MénardChief Information officerN/AN/AN/A
Dr. Josephine FubaraChief Science Officer of Consumer Health CareN/AN/AN/A
Eva Schaefer-JansenHead of Investor RelationsN/AN/AN/A
Mr. Dante BeccariaGlobal Compliance Officer & VPN/AN/AN/A
Mr. Roy PapatheodorouExec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. IntegrityN/AN/A1978
Mr. Josep CatllaHead of CommunicationsN/AN/AN/A
Mr. Pierre ChancelSr. VP of Global Diabetes and Sr. VP of Global MarketingN/AN/A1957
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Corporate Governance

Sanofis ISS Governance QualityScore, Stand 31. Juli 2022, lautet 4. Die grundlegenden Scores sind Audit: 3, Vorstand: 4, Shareholderrechte: 5, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.